Viewing nowCombinationSamsitaplus Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.

MFDS item code 202108203 · Approved 2021.12.30 · Insurance code 642308620
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood glucose levels in patients with type 2 diabetes. It is particularly prescribed when patients who have not previously received diabetes medication find it difficult to control blood sugar levels with monotherapy. Additionally, it is used when control is insufficient with metformin or sitagliptin, or when substituting for a combination therapy of these two medications. This drug also helps improve blood glucose control when used in combination with sulfonylureas or thiazolidinediones, or when combined with insulin. In other words, it is an effective medication for enhancing blood glucose control in combination with various existing therapies.
The dose of this medication for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medication should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacologic treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medication may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medication. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).
This medication may cause serious allergic reactions; therefore, if symptoms such as skin rash, hives, or difficulty breathing occur after ingestion, it should be discontinued immediately and a doctor consulted. This medication carries the risk of inducing inflammation of the pancreas known as acute pancreatitis; if symptoms such as abdominal pain, vomiting, or loss of appetite develop during treatment, medical attention should be sought immediately. One of the ingredients in this medication should not be used in patients with severely impaired renal function, and caution is required in cases of poor kidney function or dehydration. Patients with heart conditions such as heart failure or acute myocardial infarction should avoid this medication. Prior to and following exams that use iodine contrast agents, this medication should be temporarily discontinued, and should only be resumed after confirming that kidney function is normal. It is safer for women who are pregnant, may become pregnant, or are breastfeeding not to take this medication. When prescribing to the elderly, regular monitoring of kidney function and dose adjustment may be necessary. Hypoglycemic symptoms may occur during treatment, so attention should be paid to symptoms of excessively low blood sugar (such as dizziness, cold sweat, headache, etc.). Excessive alcohol consumption should be avoided while taking this medication, as alcohol intake may increase the risk of side effects. This medication may need to be temporarily discontinued around the time of surgery, so it is important to inform medical personnel if surgery is planned. Some patients may experience side effects such as joint pain or skin rash; if unusual symptoms persist, consult a healthcare provider. It is important to have regular blood tests and kidney function tests while taking this medication to check for any abnormalities. In the event of an overdose, seek medical attention immediately for appropriate treatment; some ingredients may be removed through dialysis. The risk of hypoglycemia may increase when this medication is taken with other antidiabetic agents, so consult a healthcare provider regarding interactions with other medications being taken. Adhere to the prescribed dosage and regimen; do not arbitrarily discontinue or change the treatment.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that is well-ventilated and kept at room temperature between 1 to 30 degrees Celsius. Proper storage conditions will help maintain the drug's efficacy for a longer duration.
Pink oval film-coated tablets
30 tablets/box [(10 tablets/PTP×3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.